Research programme: MKNK1/MKNK2 protein inhibitors - Eli LillyAlternative Names: Cercosporamide
Latest Information Update: 16 Jul 2016
At a glance
- Originator Eli Lilly
- Class Small molecules
- Mechanism of Action MKNK1 protein inhibitors; MKNK2 protein inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for research development in Cancer in USA (PO)
- 16 Nov 2011 Pharmacodynamics data from a Preclinical trial in Prostate cancer presented at the 23rd AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics (AACR-NCI-EORTC-2011)
- 12 Jul 2011 Early research in Cancer in USA (PO)